To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open390.1
High390.1
Low376.1
Prev. Close377.25
Avg. Traded Price380.03
Volume31,179

MARKET DEPTH

info2
Total bid0.00
Total ask0.00
OrdersQtyBid
000
000
000
000
000
AskQtyOrders
000
000
000
000
000

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

376.1014 hours ago
390.1020 hours ago
arrow

LOWER/UPPER CIRCUITS

307.50
461.20
arrow
Gujarat Themis Biosyn Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteInterest Coverage Ratio,is 195.82, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
noteDebt to Equity Ratio,of 0.12 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
noteStock Price,rose 10.67% and outperformed its sector by 10.14% in the past year.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 119.02%
Net profit growth 5Y CAGR : 55.97%
Gujarat Themis Biosyn Ltd Top mutual funds holding
arrow
Incorporated in 1981 as a joint sector company with GIIC Ltd. and Chemosyn (P) Ltd. Commenced production in August 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug Companies - Themis Medicare Ltd. Kopran Ltd. Anant & Co. Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd.. The Company entered into Technical & Financial collaboration with Yuhan Corporation South Korea. With Yuhan's know-how GTBL became India's first Company to start commercial production of Anti-tuberculosis drug Rifampicin. The company is principally engaged in the activities pertaining to manufacturing of pharmaceuticals and medicinal chemicals.
personal

Grow your wealth with more research recommendations

+91